Renzo Y Loyaga-Rendon1, Deepak Acharya2, Salpy V Pamboukian2, Jose A Tallaj2, Ryan Cantor2, Randall C Starling2, David C Naftel2, James K Kirklin2. 1. From the Division of Cardiovascular Diseases, Department of Medicine (R.Y.L.-R., D.A., S.V.P., J.A.T.), Division of Cardiothoracic Surgery, Department of Surgery (R.C.), and Department of Epidemiology, School of Public Health (R.C.), and Division of Cardiothoracic Surgery (D.N., J.K.), University of Alabama at Birmingham; and Section of Heart Failure, Department of Medicine, Cleveland Clinic Foundation, OH (R.C.S.). rloyagar@uab.edu. 2. From the Division of Cardiovascular Diseases, Department of Medicine (R.Y.L.-R., D.A., S.V.P., J.A.T.), Division of Cardiothoracic Surgery, Department of Surgery (R.C.), and Department of Epidemiology, School of Public Health (R.C.), and Division of Cardiothoracic Surgery (D.N., J.K.), University of Alabama at Birmingham; and Section of Heart Failure, Department of Medicine, Cleveland Clinic Foundation, OH (R.C.S.).
Abstract
BACKGROUND:Heart failure (HF) progression results in worsening functional capacity and end-organ compromise. HF may occur acutely or be associated with a chronic presentation. We hypothesized that the duration of HF affects outcomes after mechanical circulatory support. METHODS AND RESULTS:A total of 10 730 patients registered in Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) who received primary implant of a mechanical circulatory support device were stratified according to the duration of HF symptoms: acute HF (AHF; ≤1 month), sub-AHF (1-12 months), and chronic HF (Cr-HF; ≥ 12 months). AHF patients were younger with a higher proportion of women and white and with a lower prevalence of peripheral vascular disease and history of prior cardiac surgeries. Sixty percent of AHF patients were INTERMACS profile 1 at the time of implantation versus 24% and 13.2% in the sub-AHF and Cr-HF groups, respectively (P=0.0001). Patients with AHF had the highest utilization of biventricular support (14.4%). The estimated survival at 4 years was 58%, 51%, and 45% for the AHF, sub-AHF, and Cr-HF patients (P=0.006). The proportion of patients with AHF who received heart transplantation at 1 year was 29% compared with 22.6% in the patients with Cr-HF. After adjustment for known risk factors of adverse outcome, patients with AHF have a better late phase prognosis compared with patients with Cr-HF (hazard ratio, 0.34; P=0.0003). CONCLUSIONS: The duration of HF before durable mechanical circulatory support implant is an important variable influencing outcome. Patients with AHF had improved survival at 4 years and higher rates of transplantation at 1 year despite higher acuity of presentation.
RCT Entities:
BACKGROUND:Heart failure (HF) progression results in worsening functional capacity and end-organ compromise. HF may occur acutely or be associated with a chronic presentation. We hypothesized that the duration of HF affects outcomes after mechanical circulatory support. METHODS AND RESULTS: A total of 10 730 patients registered in Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) who received primary implant of a mechanical circulatory support device were stratified according to the duration of HF symptoms: acute HF (AHF; ≤1 month), sub-AHF (1-12 months), and chronic HF (Cr-HF; ≥ 12 months). AHF patients were younger with a higher proportion of women and white and with a lower prevalence of peripheral vascular disease and history of prior cardiac surgeries. Sixty percent of AHF patients were INTERMACS profile 1 at the time of implantation versus 24% and 13.2% in the sub-AHF and Cr-HF groups, respectively (P=0.0001). Patients with AHF had the highest utilization of biventricular support (14.4%). The estimated survival at 4 years was 58%, 51%, and 45% for the AHF, sub-AHF, and Cr-HF patients (P=0.006). The proportion of patients with AHF who received heart transplantation at 1 year was 29% compared with 22.6% in the patients with Cr-HF. After adjustment for known risk factors of adverse outcome, patients with AHF have a better late phase prognosis compared with patients with Cr-HF (hazard ratio, 0.34; P=0.0003). CONCLUSIONS: The duration of HF before durable mechanical circulatory support implant is an important variable influencing outcome. Patients with AHF had improved survival at 4 years and higher rates of transplantation at 1 year despite higher acuity of presentation.
Authors: Deepak Acharya; Renzo Y Loyaga-Rendon; Salpy V Pamboukian; José A Tallaj; William L Holman; Ryan S Cantor; David C Naftel; James K Kirklin Journal: J Am Coll Cardiol Date: 2016-04-26 Impact factor: 24.094
Authors: Eva Maria Javier Delmo; Mariano Francisco Del Maria Javier; Dietmar Böthig; Andre Rüffer; Robert Cesnjevar; Michael Dandel; Roland Hetzer Journal: Cardiovasc Diagn Ther Date: 2021-02
Authors: Amr Abdin; Stefan D Anker; Javed Butler; Andrew J Stewart Coats; Ingrid Kindermann; Mitja Lainscak; Lars H Lund; Marco Metra; Wilfried Mullens; Giuseppe Rosano; Jonathan Slawik; Jan Wintrich; Michael Böhm Journal: ESC Heart Fail Date: 2021-10-16